Lead sponsor
Axovant Sciences Ltd.
8 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
8
Trials led
0
Ongoing
3,320
Total enrollment
313
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
5
Phase 2/3
1
Phase 3
2
Trials by status
Completed
5
Terminated
3
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET StudyMMSE 12-24Ph 3Completed1,315
12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET ExtensionAge 50-86Ph 3Terminated1,099
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB StudyDementia with Lewy bodiesPh 2Completed484
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB ExtensionAge 50-86Ph 2/3Terminated240
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior DisorderAge ≥50Ph 2Terminated80
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With DementiaMultiple dementia etiologiesPh 2Completed38
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)Parkinson's disease dementiaPh 2Completed34
Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body DementiaParkinson's disease dementiaPh 2Completed30